Search

Compliance and reports

EHA is a non-governmental and not-for-profit membership organization that is guided by its mission to promote excellence in patient care, research, and education in hematology.

Read more

EBAH CME policy

Welcome to the EBAH CME Accreditation policy for EHA2025 Congress. Below you will find an overview of the EBAH CME credits that can be collected for physical attendance as well as virtual attendance of the sessions.

Read more

EHA Mentorship Program overview

Program goalsThe EHA Mentorship Program aims to:

Provide the early and mid-career European hematology community with access to mentorship that's relevant to their career stage
Expose hematologists and researchers from less professionally mobile backgrounds to career mentorship and best practices from other…

Read more

European Reference Networks, a unique opportunity to take collaboration and patient care in hematology to the next level, was a core topic at EHA 2016

On Saturday 11 June, a session in the Patient Advocacy Track focused on the emerging European Reference Networks (ERNs).

Read more

Registration & accommodation

Registration is closed. The EHA-EBMT 6th European CAR T-cell Meeting provides opportunities for students, trainees, nurses and others to join the meeting for a discounted fee.

Read more

How to apply

The CRTH 2025 call for applications is now closed. Timelines
Application CRTH 2025
Deadline: September 24, 2024 (15:00 CEST)

Notification
November 2024

Questions: training@ehaweb. orgDownload the Signature letter template.

Read more

Addressing immunoglobulin shortages: EHA and EBA’s strategic recommendations at the EMA

In recent years, shortages of immunoglobulins (Ig) have become a growing concern in the European Union (EU). Since 2018, the European Medicines Agency (EMA)—the EU agency that evaluates and supervises medicines—has received an increasing number of shortage reports.

Read more

SGN-CD33A Combined with Hypomethylating Therapy Produces High Remission Rates among Older Patients with AML

Acute myeloid leukemia (AML) is an aggressive form of blood cancer in which the majority of cases express CD33 on the surface of the leukemia cells.

Read more